Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) saw a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 1,620,000 shares, an increase of 51.4% from the July 31st total of 1,070,000 shares. Based on an average trading volume of 559,700 shares, the days-to-cover ratio is presently 2.9 days.
Wall Street Analyst Weigh In
Several brokerages have weighed in on BCLI. StockNews.com started coverage on Brainstorm Cell Therapeutics in a report on Friday. They issued a “hold” rating for the company. Maxim Group raised shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Thursday, July 11th.
Check Out Our Latest Stock Report on Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Stock Performance
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). During the same quarter last year, the firm earned ($0.27) EPS. On average, sell-side analysts expect that Brainstorm Cell Therapeutics will post -0.14 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is currently owned by institutional investors and hedge funds.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Featured Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- Investing In Preferred Stock vs. Common Stock
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- Insider Trades May Not Tell You What You Think
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Why Are These Companies Considered Blue Chips?
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.